Media contact: Stéphanie Bardon – communication@genethon.fr – 01.69.47.12.78
September 9, 2019
A gene therapy based clinical trial for Fanconi anemia patients offers its first successful results
June 26, 2019
First in vivo proof-of-concept in Steinert’s myotonic dystrophy, a neuromuscular disease
May 24, 2019
Towards a clinical trial for gamma-sarcoglycanopathy, limb-girdle muscular dystrophy
February 25, 2019
Clinical Proof-of-Concept Data for OTL-102 for the Treatment of X-CGD
December 10, 2018
Genethon announces dosing of the first patient with Crigler–Najjar Syndrome
October 5, 2018
Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy Study Published in Nature Communications by Généthon and Selecta Biosciences
March 13, 2018
AveXis Enters into Licensing Agreement with Genethon
AveXis, Inc. (NASDAQ: AVXS) and Genethon today announced they have entered into an exclusive, worldwide license agreement for in vivo gene therapy delivery of AAV9 vector into the central nervous system (CNS) for the treatment of spinal muscular atrophy (SMA). (read more)
February 12, 2018
Genethon starts a clinical trial to test a gene therapy treatment for a rare liver disease, Crigler-Najjar Syndrome
December 15, 2017
A gene therapy alliance in X-linked chronic granulomatous disease with Orchard Therapeutics
Orchard Therapeutics (“Orchard”), a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies announces today a strategic alliance with Généthon, to develop gene therapy for X-linked chronic granulomatous disease (“X-CGD”)…. (read more)
September 21, 2017
Audentes Therapeutics announces dosing of first patient in ASPIRO for the treatment of X-Linked Myotubular Myopathy
July 25, 2017
Restore muscle strength in Duchenne muscular dystrophy through microdystrophin
June 21, 2017
New partnership for the treatment of Duchenne muscular disease (DMD)
Sarepta Therapeutics, a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, and Genethon, have signed a gene therapy research collaboration to jointly develop treatments for Duchenne… (read more)
April 5, 2017
